PT-141
PT-141
PT-141 10mg (Bremelanotide) – Research Peptide
Melanocortin Receptor Agonist for Neuroendocrine & Sexual Function Research
PT-141, also known as bremelanotide, is a synthetic cyclic peptide and melanocortin receptor agonist that has attracted significant scientific interest for its effects on central nervous system pathways involved in sexual motivation, arousal, neuroendocrine signaling, and melanocortin biology.
Unlike compounds that primarily influence peripheral vascular mechanisms, PT-141 has been studied for its centrally mediated activity through melanocortin receptors, particularly receptors expressed within regions of the central nervous system.
Research involving PT-141 has contributed to a broader understanding of the relationship between the central melanocortin system, neural signaling, sexual behavior, and neuroendocrine regulation.
ICAME Pharmacy PT-141 is intended strictly for laboratory research and development purposes. It is not intended for human or veterinary use.
What is PT-141?
PT-141 is the developmental designation for bremelanotide, a synthetic cyclic peptide derived from research involving analogues of α-melanocyte-stimulating hormone (α-MSH).
Bremelanotide is structurally related to melanocortin peptides and interacts with several members of the melanocortin receptor (MCR) family.
The melanocortin system consists of five receptor subtypes:
MC1R • MC2R • MC3R • MC4R • MC5R
These receptors are distributed across different tissues and participate in diverse physiological processes.
MC3R and MC4R are particularly important in neuroscience because they are prominently expressed within the central nervous system.
PT-141 has therefore become a useful molecule for investigating the relationship between melanocortin signaling and centrally mediated physiological responses.
The Melanocortin System
The melanocortin system is a complex biological signaling network involving endogenous peptides such as melanocyte-stimulating hormones and their receptors.
Melanocortin signaling participates in several areas of physiology, including:
- Neural signaling
- Sexual function
- Energy homeostasis
- Feeding behavior
- Pigmentation
- Neuroendocrine regulation
- Autonomic responses
Of particular interest for PT-141 research are the MC3 and MC4 receptors, both of which are associated with neural melanocortin pathways.
PT-141 and MC4R Signaling
The melanocortin-4 receptor (MC4R) is one of the most extensively studied targets associated with bremelanotide.
MC4R is expressed in multiple regions of the central nervous system, including hypothalamic regions involved in the integration of behavioral and physiological signals.
Research suggests that activation of melanocortin pathways can influence neural circuits associated with sexual motivation and arousal.
In female sexual-response research, one proposed mechanism involves activation of MC4R-associated neurons in the medial preoptic area of the hypothalamus, potentially affecting downstream neurotransmitter signaling.
However, the complete mechanism through which bremelanotide influences sexual desire remains incompletely understood.
Proposed Mechanism of Action
PT-141 acts as an agonist at melanocortin receptors.
Rather than primarily targeting peripheral blood vessels, its research profile is associated with modulation of signaling within the central nervous system.
A simplified research model can be represented as:
PT-141 (Bremelanotide)
↓
Melanocortin Receptor Activation
↓
MC4R / MC3R-Associated Neural Pathways
↓
Hypothalamic & Neurotransmitter Signaling
↓
Sexual Motivation • Arousal • Neuroendocrine Responses
This central mechanism distinguishes melanocortin research from approaches that primarily target local vascular physiology.
PT-141 and Sexual Function Research
One of the most extensively investigated aspects of PT-141 is its relationship with sexual function and behavior.
Early preclinical studies demonstrated that melanocortin receptor stimulation could influence sexual responses in animal models.
These findings were followed by human investigations.
Early clinical research in men reported changes in erectile activity following administration of PT-141, while research in premenopausal women investigated physiological and subjective measures of sexual arousal and desire.
These studies contributed to the development of bremelanotide as a pharmacologically active melanocortin agonist.
PT-141 and Female Sexual Response Research
The neurobiology of female sexual desire involves interactions between numerous neurotransmitter and hormonal pathways.
These include signaling involving:
Dopamine
Norepinephrine
Serotonin
Sex hormones
Melanocortin pathways
Research suggests that melanocortin receptors participate in excitatory pathways involved in female sexual response.
One proposed model suggests that MC4R activation within hypothalamic regions may influence dopaminergic signaling, which is associated with motivation and sexual desire.
PT-141 therefore provides an important experimental tool for studying interactions between melanocortin signaling, dopamine pathways, and female sexual neurobiology.
PT-141 and Male Sexual Function Research
PT-141 has also been extensively investigated in experimental models of male sexual physiology.
Animal studies demonstrated melanocortin-mediated erectile responses, which contributed to subsequent clinical investigations in men.
Early human studies reported dose-related increases in erectile activity in both healthy participants and individuals with erectile dysfunction.
The scientific importance of these observations lies partly in the proposed central mechanism.
Traditional erectile-function research frequently focuses on peripheral vascular mechanisms. Melanocortin agonists provide an alternative experimental model involving neural pathways associated with sexual response.
This makes PT-141 relevant to research examining the relationship between:
Central Neural Signaling → Sexual Motivation → Physiological Sexual Response
PT-141 and Dopaminergic Signaling
Dopamine is an important neurotransmitter involved in motivation, reward, attention, and sexual behavior.
Experimental models suggest that melanocortin signaling may interact with dopaminergic pathways within regions of the hypothalamus associated with sexual function.
For this reason, researchers have investigated whether MC4R activation can influence dopamine release and thereby contribute to changes in sexual motivation and behavioral response.
This interaction represents an important area of PT-141 research because it connects melanocortin receptor pharmacology with broader neurochemical signaling systems.
PT-141 and Central Nervous System Research
MC3R and MC4R are often described as neural melanocortin receptors because of their prominent expression within the central nervous system.
Research involving these receptors extends considerably beyond sexual biology.
The central melanocortin system participates in:
Behavioral signaling
Energy homeostasis
Autonomic regulation
Motivational pathways
Neuroendocrine signaling
PT-141 therefore provides researchers with a pharmacological tool for investigating melanocortin receptor activation in the context of CNS physiology.
Potential Research Applications
PT-141 may be of interest in controlled scientific investigations involving:
- Melanocortin receptor biology
- MC4R signaling
- MC3R signaling
- Central nervous system research
- Sexual behavior research
- Female sexual-response biology
- Male sexual-response biology
- Neuroendocrine signaling
- Hypothalamic pathways
- Dopaminergic signaling
- Motivation and reward pathways
- Melanocortin pharmacology
- Receptor–ligand interaction studies
- Behavioral neuroscience
- Experimental pharmacology
Its centrally mediated pharmacological profile makes PT-141 particularly interesting for research comparing neural and peripheral mechanisms involved in physiological sexual responses.
PT-141 vs. Peripheral Sexual-Function Research
A particularly interesting characteristic of PT-141 is that its mechanism differs from compounds whose principal research target is peripheral vascular signaling.
Peripheral Pathways
Many established approaches to erectile-function pharmacology involve mechanisms affecting vascular smooth muscle and local blood flow.
Melanocortin Pathways
PT-141 research instead focuses substantially on:
Brain
↓
Hypothalamic melanocortin receptors
↓
Neural / neurotransmitter signaling
↓
Behavioral & physiological sexual response
This distinction has made PT-141 particularly valuable in research investigating the central neurological regulation of sexual function.
Clinical Research Background
Bremelanotide has a substantially different evidence base from many experimental research peptides because it progressed through extensive clinical development.
Studies investigated bremelanotide in both male and female sexual-function research.
Development ultimately resulted in an FDA-approved bremelanotide medicine for a specific indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in certain premenopausal women.
However, this regulatory history should not be interpreted to mean that generic PT-141 research products are equivalent to the approved pharmaceutical formulation.
ICAME Pharmacy PT-141 should therefore remain clearly positioned as a research product rather than as an approved medicine.
Safety Research
Bremelanotide has been extensively evaluated for safety during clinical development.
Reported adverse effects associated with the approved drug include nausea, flushing, headache, vomiting, injection-site reactions, and transient increases in blood pressure.
Melanocortin receptor activity can also influence pigmentation. The FDA labeling explains that interaction with MC1R is associated with increased melanin expression and pigmentation.
These observations illustrate the broader biological activity of melanocortin receptors and reinforce the importance of controlled research when investigating PT-141.
PT-141 Research Overview
Compound
PT-141 / Bremelanotide
Classification
Synthetic Cyclic Peptide
Research Family
Melanocortin Receptor Agonist
Principal Research Targets
MC4R • MC3R • Melanocortin Signaling
Primary Research Areas
Neuroendocrine Biology • Sexual Function • CNS Signaling • Behavioral Neuroscience
Product Information
Product Name: PT-141
Alternative Name: Bremelanotide
Brand: ICAME Pharmacy
Product Category: Research Peptide
Research Classification: Melanocortin Receptor Agonist
Research Area: Melanocortin Signaling / Neuroendocrine Biology / CNS Research
Intended Use: Laboratory Research & Development Only
Batch-specific information including purity, analytical methodology, Certificate of Analysis (COA), batch/lot identification, and validated storage conditions should be provided according to the documentation associated with each individual production batch.
Important Research Use Notice
FOR RESEARCH USE ONLY (RUO)
This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical, and scientific research purposes.
Not for human or veterinary use. Not for diagnostic, therapeutic, sexual-enhancement, or performance-enhancing purposes. Not for direct administration to humans or animals.
PT-141 is also known as bremelanotide, an active pharmaceutical ingredient associated with an FDA-approved prescription medicine. The existence of an approved bremelanotide medicine does not establish that research-grade PT-141 products are approved medicines, therapeutically interchangeable, or suitable for human use.
Information presented on this page is intended solely for scientific and educational purposes and should not be interpreted as medical advice, prescribing information, dosage guidance, or instructions for human use.
About ICAME Pharmacy
ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.
Our portfolio focuses on compounds relevant to contemporary areas of molecular biology, peptide research, metabolic science, neuroendocrine biology, and experimental life sciences.
Product information is presented with an emphasis on responsible research use, scientific transparency, clear product identification, and professional research applications.
For batch-specific documentation, analytical information, and product inquiries, please contact ICAME Pharmacy.